These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

154 related items for PubMed ID: 2517455

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Pro-urokinase: physiochemical properties and promotion of its fibrinolytic activity by urokinase and by tissue plasminogen activator with which it has a complementary mechanism of action.
    Gurewich V.
    Semin Thromb Hemost; 1988 Jan; 14(1):110-5. PubMed ID: 3127884
    [No Abstract] [Full Text] [Related]

  • 3. [Advances in fibrinolysis mediated by vascular endothelial cells].
    Zhou QS.
    Sheng Li Ke Xue Jin Zhan; 1990 Oct; 21(4):318-22. PubMed ID: 2129251
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Inhibitors of fibrinolysis with special reference to anti-t-PA (inhibitor of the tissue plasminogen activator)].
    Félez J, Rueda F.
    Sangre (Barc); 1985 Oct; 30(4-C):779-86. PubMed ID: 3937250
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
    Camiolo SM, Greco WR.
    Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
    [Abstract] [Full Text] [Related]

  • 10. [Significance of urokinase and its inhibitors in the invasiveness and metastasing of malignant tumors].
    Halámková J, Kiss I, Tomášek J, Pavlovský Z, Tuček S, Penka M.
    Vnitr Lek; 2012 Feb; 58(2):129-34. PubMed ID: 22463093
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
    Sabovic M, Lijnen HR, Keber D, Collen D.
    Thromb Haemost; 1989 Dec 29; 62(4):1083-7. PubMed ID: 2515603
    [Abstract] [Full Text] [Related]

  • 14. The plasminogen activator system and cancer.
    McMahon B, Kwaan HC.
    Pathophysiol Haemost Thromb; 2008 Dec 29; 36(3-4):184-94. PubMed ID: 19176991
    [Abstract] [Full Text] [Related]

  • 15. The role of the fibrinolytic system in corneal angiogenesis.
    Vogten JM, Reijerkerk A, Meijers JC, Voest EE, Borel Rinkes IH, Gebbink MF.
    Angiogenesis; 2003 Dec 29; 6(4):311-6. PubMed ID: 15166500
    [Abstract] [Full Text] [Related]

  • 16. A highly sensitive chromogenic microtiter plate assay for plasminogen activators which quantitatively discriminates between the urokinase and tissue-type activators.
    Karlan BY, Clark AS, Littlefield BA.
    Biochem Biophys Res Commun; 1987 Jan 15; 142(1):147-54. PubMed ID: 3101684
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Role of single chain pro-UK on the initiation and regulation of fibrinolysis].
    Arimura H, Kasai S, Nishida M, Suyama T.
    Rinsho Byori; 1989 Apr 15; Spec No 81():107-17. PubMed ID: 2502639
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Plasminogen activation and regulation of pericellular proteolysis.
    Saksela O.
    Biochim Biophys Acta; 1985 Nov 12; 823(1):35-65. PubMed ID: 2413894
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.